Welcome to the Rockland Technimed Ltd. Media Center, where you can review news, learn about upcoming events and access publications and abstracts related to our Oxy-17® technology platform.For media inquiries, please contact: email@example.com
RTL is a member of MTEC (Medical technology enterprise consortium) since January 2021 and has been invited to DOD funding and contract RFI’s for use to enhance oxygen delivery.
Rockland Technimed Ltd has been awarded the Healthcare & Pharmaceutical Awards 2016 for "Best Theranostic Imaging Company 2016 - USA & Most Disruptive Nano-Technology: OxyFusion™"
Conference link: http://techconnectworld.com/World2016/ "Rockland Technimed, Ltd. ", has been ACCEPTED to SHOWCASE its disruptive Nano-technology OxyFusion™ MRI medium at this year's TechConnect World Innovation Summit & Expo, co-located with the National Innovation Summit and National SBIR/STTR Conference, May 23-25, just outside Washington, D.C., at the Gaylord National Resort & Convention Center, National Harbor, MD.
Rockland Technimed Ltd is a Theranostics company, committed to the early diagnosis and treatment of hypoxic injury. Rockland's disruptive Nano-technology OxyFusion™ MRI medium enriched with its patented Oxy-17® process may set the new Gold standard of Cellular metabolic imaging without radiotracers.Website: www.oxy-17.com
Hazards of Current Imaging Agent in Use:Biohazard hazard Reports of Gadolinium: FDA Radiological Society of North America
Environmental hazard Reports of Gadolinium:NIH Report American Chemical Society Stanford University Global Regulatory News
• U.S. Food and Drug Administration Information on Gadolinium-Based Contrast Agents • Health Canada Advises Canadians of Safety Issues Related to Gadolinium-Containing Contrast Agents Used in Magnetic Resonance Imaging (MRI) • UK Medicines and Healthcare products Regulatory Agency Drug Safety Update on Gadolinium-containing Contrast Agents: New Advice to Minimise the Risk of Nephrogenic Systemic Fibrosis • European Medicines Agency Makes Recommendations to Minimise Risk of Nephrogenic Systemic Fibrosis with Gadolinium-containing Contrast AgentsPublications and Abstracts Click on this link for Publications & Abstracts in PDF format